Medicines Australia pays tribute to long standing Board Member

Medicines Australia wishes to congratulate Mr Bruce Goodwin on his retirement. Announced today, Mr Goodwin will finish as the Managing Director of Janssen Australia and New Zealand in December.

Bruce has been a Director of the Medicines Australia Board from May 2009 until September 2012 and again from December 2016 to the present.

During his tenure as a Director, Bruce has also served on the Medicines Australia Finance and Audit Committee and as member and later as the Chair of the Performance, Remuneration and Governance Committee.

Dr Anna Lavelle, Chair, Medicines Australia said: “Bruce has exerted a huge influence on Medicines Australia as Board Director and Chair of the Performance and Governance sub-committee.  I appreciate greatly the insightful, fearless and considered advice that Bruce brings to complex discussions. He deserves our thanks for his objective and focussed efforts on behalf of all member companies.”

“I wish him every happiness in the future and greatly value his legacy and his friendship,” said Dr Lavelle.

Medicines Australia CEO, Elizabeth de Somer paid tribute to Mr Goodwin saying: “Bruce has been a dedicated and energetic Board member, who has provided sage and frank guidance and will be greatly missed.

“Bruce has been a strong voice for industry and most importantly patients and has been instrumental in shaping the policy settings that ensure our industry continues to thrive in Australia.

“I have greatly valued Bruce’s experience, his unwavering support of Medicines Australia and the guidance he has provided to me personally.  I wish him all the best in his retirement,” said Ms de Somer.

Bruce Goodwin, Managing Director, Janssen Australia and New Zealand said: “I have had the privilege to serve on the Medicines Australia Board both times I have been the Managing Director of Janssen Australia and New Zealand. As a Board member I’ve been able to work alongside numerous talented colleagues who, like myself, believe in our industry and its value to the healthcare sector.

“Having worked in the innovative medicines industry for almost four decades I know that everyone in the sector strives for the betterment of human health. It has been a privilege to work in a sector which has done such an extraordinary amount to improve the health, of not just of Australians, but people all over the world.

“This year the innovative medicines industry has been at the forefront of tackling the pandemic and I couldn’t be prouder to be leaving my Board role with Medicines Australia at a time where we have collectively come together to flight COVID-19,” said Mr Goodwin.

Ends

More information – Natalie Wimmer – Media Manager, Medicines Australia – 0450728660 – nwimmer@medaus.com.au